Drugs / Depleted Stem Cell Transplant
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04784052 | Dec 2021 → Dec 2027 expected | Fanconi anemia | Porteus, Matthew, MD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Depleted Stem Cell Transplant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04784052 ↗ |
| Modality | Cell therapy | “develop a cell therapy for Fanconi Anemia” NCT04784052 ↗ |
| Route | Intravenous | “TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen” NCT04784052 ↗ |